Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose PK study of CHF 6001 in asthmatic adolescents vs adults
2024-516483-29-00Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tanimilast in asthma (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: CHF 6001 Cmax and AUC0-t. Started Jan 2025; status: completed.
02
Drugs
tanimilast
03
Conditions
asthma
Beyond the preview
Go deeper on 2024-516483-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516483-29-00.